Vernalis collaborates with pharma and biotech partners (including Servier, Pierre Fabre, Novartis, GSK and Lundbeck) to solve early drug discovery challenges. Via flexible collaboration models our services include HitID, FBDD, SBDD, advanced biophysics, structural biology, assay development, cell-based assays, molecular modelling and medicinal chemistry. As an independent subsidiary of HitGen, we also offer world leading DEL technology and expanded services within Vernalis led programmes.